Q4 FY23
• Operating revenue was ₹486.0 cr. compared to ₹418.0 cr. in Q4FY22,
an increase of 16.3% YoY.
• Price erosion for Rx products in the US for the quarter was stable.
• Gross profit was ₹242.1 cr., with a Gross margin of 49.8%
• EBITDA was ₹109.5 cr., with an EBITDA margin of 22.5%. The EBITDA
margin increased YoY by 730 bps, on account of the normalization of
freight expenses and cost optimization initiatives
• PBT was ₹104.2 cr. PAT stood at ₹82.7 cr (+178.9% YoY)
• EPS was Rs 2.0 (+185.5% YoY)
Investor Presentation:
https://www.bseindia.com/xml-data/corpfiling/AttachLive/acb3439c-78f7-43a7-99aa-f0468efb43b3.pdf
| Subscribe To Our Free Newsletter |
